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Abstract 33 
Context: Alterations in the cAMP signalling pathway are common in hormonally-active endocrine 34 
tumors. Somatic mutations at GNAS are causative in 30-40% of GH-secreting adenomas. Recently, 35 
mutations affecting the USP8 and PRKACA gene have been reported in ACTH-secreting pituitary 36 
adenomas and cortisol-secreting adrenocortical adenomas, respectively. However, the pathogenesis of 37 
many GH-secreting adenomas remains unclear. 38 
Aim: Comprehensive genetic characterization of sporadic GH-secreting adenomas and identification of 39 
new driver mutations. 40 
Design: Screening for somatic mutations was performed in 67 GH-secreting adenomas by targeted 41 
sequencing for GNAS, PRKACA, and USP8 mutations (n=31) and next-generation exome-sequencing 42 
(n=36).  43 
Results: By targeted sequencing known activating mutations in GNAS were detected in 5 cases 44 
(16.1%), while no somatic mutations were observed in both PRKACA and USP8. Whole exome 45 
sequencing identified 132 protein-altering somatic mutations in 31/36 tumors with a median of 3 46 
mutations per sample (range: 1-13). The only recurrent mutations have been observed in GNAS 47 
(31.4% of cases). However, 7 genes involved in cAMP signalling pathway were affected in 14 of 36 48 
samples and 8 samples harbored variants in genes involved in the calcium signalling or metabolism. 49 
At the enrichment analysis, several altered genes resulted to be associated with developmental 50 
processes. No correlation between genetic alterations and the clinical data was observed.  51 
Conclusions: This study provides a comprehensive analysis of somatic mutations in a large series of 52 
GH-secreting adenomas. No novel recurrent genetic alterations have been observed, but the data 53 
suggest that beside cAMP pathway calcium signalling might be involved in the pathogenesis of these 54 
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Introduction 61 
Pituitary tumors represent approximately 15% of all primary intracranial lesions. Growth hormone 62 
(GH)-secreting pituitary adenomas are the second most frequent type of hormone-producing pituitary 63 
tumors, after prolactin-secreting adenomas1. Excessive secretion of GH causes gigantism during 64 
childhood and acromegaly in adults, with significant morbidity due to clinical complications involving 65 
cardiovascular, respiratory, and metabolic systems.2, 3 66 
The monoclonal origin of most pituitary adenomas indicates that these tumors derive from the 67 
replication of a single cell that acquired growth advantage. The latter has been suggested to result from 68 
genetic or epigenetic alterations leading to activation of proto-oncogenes or inactivation of tumor 69 
suppressor genes4, 5. However, despite intensive investigations, little is known about the genetic causes 70 
of pituitary adenomas. The only mutations identified to date in a significant proportion (30-40%) of 71 
sporadic GH-secreting adenomas occur in the gene encoding the α subunit of the stimulatory G protein 72 
(GNAS).6-9 These somatic activating mutations (gsp mutations), found in codon 201 and 227, prevent 73 
hydrolysis of GTP, leading to a constitutive activation of the cAMP pathway, which in somatotrophs 74 
and in other endocrine cells acts as a mitogenic signal10, 11.  In somatotrophs the GNAS transcript is 75 
expressed mainly from the maternal allele, due to tissue-speciﬁc paternal imprinting12, 13. Consistently, 76 
gsp mutations in sporadic GH-secreting adenomas are found on the maternal allele14 and partial loss of 77 
this imprinting is present in tumors negative for gsp mutations15, further supporting the involvement of 78 
GNAS locus in pituitary tumorigenesis. So far, the screening for mutations in other G-protein subunits 79 
in pituitary tumors has given negative results.16-18  80 
Genetic alterations in other genes involved in cAMP signalling have been identified as cause 81 
of other endocrine tumors. A reduced expression and/or function of the PKA regulatory subunit type 82 
Iα (PRKAR1A) due to loss-of-function mutations, leading to an abnormal cAMP pathway activation, 83 
causes GH-secreting pituitary adenomas in Carney complex, an autosomal dominant familial 84 
syndrome19, 20. To date, mutations of PRKAR1A gene have been rarely found in sporadic pituitary 85 
tumors21, 22, although a reduced PRKAR1A expression resulting from increased proteosomal 86 
degradation has been described in sporadic GH-secreting tumors10. Reduced cAMP degradation 87 
caused by mutations in PDE11A and PDE8B, coding for members of the phosphodiesterase (PDE) 88 
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family, have been involved in adrenocortical hyperplasia, adenomas and cancer as well as in testicular 89 
germ cell tumors23, 24. However, genetic variants of PDE11A4 contribute only marginally to the 90 
development of GH-secreting adenomas25. Recently, mutations affecting the gene encoding the 91 
catalytic subunit α of the PKA (PRKACA) have been reported in a large proportion of cortisol-92 
secreting adrenocortical adenomas26-30, resulting in increased PKA activity31. Nevertheless, no hot spot 93 
mutations of PRKACA have been identified in a large cohort of GH-secreting adenomas32. Finally, a 94 
recurrent somatic mutation in the GPR101 gene, which encodes an orphan G-protein–coupled 95 
receptor, has been recently reported in some adults with acromegaly (4% of cases).33 96 
In addition, epidermal growth factor receptor (EGFR) overexpression has been described in 97 
hormonally active pituitary adenomas34 and role for EGF and its receptor in the development and/or 98 
progression of pituitary tumors has been hypothesized35. Dominant mutations in the deubiquitinase 99 
USP8 gene that promote activation of EGFR signalling have been also found in ACTH-secreting 100 
pituitary adenomas by exome sequencing36. Finally, germline mutations of genes such as the aryl 101 
hydrocarbon receptor interacting protein (AIP), the menin (MEN1) and the p27 (CDKN1B) have been 102 
reported in genetic syndromes associated with acromegaly (i.e. familial isolated pituitary adenoma and 103 
multiple endocrine neoplasia type 1 and 4) and in a low percentage of young acromegalic patients.37  104 
Recently, Valimäki et al. investigated a small group of 12 patients with GH-secreting 105 
adenomas by whole-genome sequencing and SNP array and did not find any novel recurrent genetic 106 
alteration.38 Aim of the present study was to perform a comprehensive genetic characterization of a 107 
large series of GH-secreting adenomas to identify novel genetic alterations potentially involved in 108 
tumorigenesis and/or in clinical outcome. To this aim, we used both targeted direct sequencing of 109 
GNAS, PRKACA and USP8 genes and next-generation exome sequencing. 110 
 111 
Material and methods 112 
Tissue samples, patients and clinical annotations 113 
Sporadic GH-secreting adenomas without familial or syndromic presentation were recruited in the 114 
present study. Accordingly, a total of 81 fresh frozen tumors were collected from 4 different 115 
participating European centers. If available, corresponding peripheral blood was also collected for the 116 
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analysis. Inclusion criteria for participating in the study were a certified histological diagnosis of 117 
benign GH-secreting adenomas and available clinical data. The DNA was isolated as described 118 
previously.39  Qualitative and quantitative evaluation of the DNA was assessed by electrophoresis in a 119 
1% agarose gel and spectro-photometrically at 260 nm, respectively. At the first screening, 14 tumor 120 
samples have been excluded due to insufficient DNA quality, so that the final series included a total of 121 
67 GH-secreting adenomas. Among them, the tumor samples were subdivided into two groups 122 
according to the availability of corresponding leukocyte-DNA essential for next generation whole 123 
exome-sequencing. Thus, 31 tumor samples underwent targeted direct sequencing for the analysis of 124 
selected genes (GNAS, PRKACA and USP8) (Group 1), while the remaining 36 cases with 125 
corresponding leukocyte-DNA were investigated by whole exome-sequencing (Group 2).  126 
 Clinical parameters, such as sex, age at diagnosis, date of surgery, tumor size, GH and IGF-I 127 
levels, presence of acromegaly-related complications, as well as follow-up data were collected for all 128 
patients at the local centers. All the patients gave written informed consent and the study was 129 
approved by the ethics committee at each participating institution. 130 
 131 
Targeted and whole-exome sequencing and data analysis  132 
For the targeted sequencing analysis we focused on gene domains harboring alterations known or 133 
supposed biologically relevant in endocrine active tumors, i.e. known gain-of-function GNAS 134 
mutations (codon 201 and 227), mutations in the catalytic domain of the PRKACA (exon 7 and 8) and 135 
in the 14-3-3- binding domain and the MIT (Microtubule Interacting and Transport)-domain (exons 1, 136 
2, 3) of the USP8, which is reported to be involved in regulating USP8 catalytic function. In addition, 137 
we also evaluated the presence of the known hot spot GNAS mutations. The primers used for the 138 
targeted direct sequencing were generated with the Program Primer3Plus39. 139 
The complete list of the primers is reported in the Supplementary Table 1. In brief, PCR was 140 
performed on 1 µl of diluted DNA (2 ng/µl) in a final volume of 25 μl containing 1,5 mM MgCl2, 0,2 141 
µM of each primer, 200 μM dNTPs and 1 U Taq DNA Polymerase. The reaction was started with an 142 
initial 95 oC denaturation step for 3 min, followed by 30 cycles of denaturation at 93 °C (20 sec), 143 
annealing at 58 °C (30 sec) and elongation at 72 °C (1 min). Direct sequencing of PCR products was 144 
Ronchi et al., 6 
 
performed using the QuickStart Cycle Sequencing Kit (ABSciex) on a CEQ8000 DNA Analyzer 145 
(ABSciex). 146 
For the next generation sequencing, exomes were enriched in solution and indexed with the 147 
use of the SureSelect XT Human All Exon 50Mb kit, version 5 (Agilent Technologies, Santa Clara, 148 
CA, USA). Sequencing was performed as paired-end reads of 100bp on a HiSeq2500 systems 149 
(Illumina, S. Diego, CA, USA) generating 8-14 Gb of sequence and an average depth of coverage 150 
between 110x and 170x on target regions. More than 95% of the target regions were covered 20 times 151 
or more. Pools of 12 indexed libraries were sequenced on four lanes. Image analysis and base calling 152 
were performed with the use of Real-Time Analysis software (Illumina). Reads were aligned against 153 
the human assembly hg19 (GRCh37) using Burrows-Wheeler Aligner (BWA v 0.7.5a). Variant 154 
detection was done as described earlier.26  155 
Somatic variants have been evaluated by Polymorphism Phenotyping v2 tool (PolyPhen-2)40 156 
and SIFT algorithm (http://sift.jcvi.org/index.html)41. An unsupervised complete linkage clustering 157 
including the most relevant somatic mutations was performed by the Hamming distance as a similarity 158 
metric. The Gene Set Enrichment Analysis (GSEA) software was used for the gene enrichment and the 159 
functional annotation (MSigDB database v5.0)42. A canonical pathway analysis (1330 gene set) and a 160 
gene family analysis were also performed with the same software. 161 
 162 
Statistical analysis 163 
Median, interquartile range (IQR), and frequency were used as descriptive statistics. IGF-I values were 164 
expressed as percentage of the upper limit of the normal range (%ULN). The Fisher’s exact test or the 165 
Chi-square test were used to investigate dichotomic variables, while a two-sided t test (or non-166 
parametric test) was used to test continuous variables. A non-parametric Kruskal-Wallis test, followed 167 
by the Bonferroni post-hoc test, was used for multiple comparisons among several groups for non-168 
normal distributed variables. Correlations and 95% confidence intervals (95%CI) between the total 169 
number of mutations and different clinical parameters were evaluated by linear regression analysis. 170 
Statistical analyses were performed using the GraphPad Prism (version 5.0, La Jolla, CA, USA) and 171 
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SPSS (PASW Version 21.0, SPSS Inc., Chicago, IL, USA) software. P values <0.05 were considered 172 




Targeted DNA sequencing (Group 1) 177 
A total of 31 patients affected by GH-secreting adenomas were included in this group. Minimum 178 
clinical data were available for 17 of them (10M&7F; median age: 46 yrs, range: 19-64; 16 179 
macroadenomas and 1 microadenoma; median basal GH levels: 24.3 ng/mL, range: 2.3-333; median 180 
IGFI %ULN: 391, range: 266-590).  181 
We observed the presence of known activating GNAS mutations in 5 out of 31 evaluated samples 182 
(16.1% of cases), i.e. a p.Arg201Cys substitution in 4 samples and a p.Gln227Leu in 1 sample. We did 183 
not identify any mutation in all the evaluated exons of PRKACA and USP8 (Table 1). However, we 184 
detected different polymorphisms in the USP8 gene: exon 1 (rs3131575 T/G heterozygous in 8 cases 185 
and homozygous in 1 case, rs11632697 G/C heterozygous in 14 cases and homozygous in 1 case, 186 
rs11632708 C/T heterozygous in 13 cases and homozygous in 1 case) and 14-3-3 binding domain 187 
(rs11638390 A/G heterozygous p.T739A in 14 cases and homozygous in 1 case) (Table 1). Allele 188 
frequencies did not differ significantly from frequencies reported in dbSNP database 189 
(http://www.ncbi.nlm.nih.gov/SNP/) (Supplementary Table 2).  190 
 191 
Next-generation exome-sequencing (Group 2) 192 
 193 
The histopathological and clinical parameters for the patients included in this analysis are reported in 194 
the Table 2. At the whole-exome sequencing, we identified a total of 132 protein-altering somatic 195 
mutations in 36 samples, resulting in a median of 3 somatic mutations in exonic regions per sample 196 
(range: 0-13). The genetic alterations included 109 missense and 7 nonsense mutations, 12 frameshift, 197 
2 direct splicing and 2 indel variations. According to the PolyPhen-2, 39 mutations were classified as 198 
probably damaging, 25 as possibly damaging, and 41 as benign. The entire list of the somatic 199 
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mutations including localization, gene symbols and transcripts is reported in the Supplementary Table 200 
3. 201 
We identified a subgroup of patients without any mutation (negative, n=5), a subgroup with a 202 
low number of mutations (n 1-3, n=14) and a subgroup with a high number of mutations (n >3, n=17) 203 
(Figure 1). No significant correlation was observed between the total number of mutations and the 204 
evaluated clinical data, such as sex, age, tumor size and extension, and the initial GH levels. 205 
The most frequent genetic alterations were the known gain-of-function mutations in the GNAS 206 
gene. Specifically, they were detected in 11 cases (31.4% of total, 10 of them being females), 207 
encoding p.Arg201Cys substitution in 7 samples, p.Arg201His in 2 samples and p.Gln227Leu in 2 208 
samples. No difference was observed in total number of mutations between the tumors with or without 209 
GNAS mutations (Figure 1). No further genetic alterations were found in more than one sample in this 210 
series. Even comparing the list of the mutated genes with that of a recent paper on whole-genome 211 
sequencing in 12 GH-secreting adenomas37, no additional recurrent somatic genetic alterations were 212 
observed.  213 
However, some non-recurrent heterozygous somatic variants were observed in genes encoding 214 
G-protein coupled receptors (GPCR), such as the chemokine receptor 10 (CCR10) and the olfactory 215 
receptor OR51B4, which are coupled to the Gs protein (activation of the cAMP signalling pathway), 216 
and the M3 muscarinic cholinergic receptor (CHRM3), which functions through Gq (activation of the 217 
inositol trisphosphate/calcium signalling pathway). Moreover, other non-recurrent alterations were 218 
found in genes coding for proteins involved in cAMP signalling pathway other than GNAS, such as the 219 
α2 catalytic subunit of the AMP-activated protein kinase (PRKAA2), the G-protein-coupled receptor 220 
kinase 3 (GRK3, alias ADRBK2), the A1 subunit of the lysosomal H+ ATPase (ATP6V0A1). Taken 221 
together, the mutations in genes involved in the cAMP signalling affected 14/36 samples (38.9% of 222 
total). Among them, 9 samples presented only GNAS mutations, 2 samples mutations at GNAS and 223 
other genes of the cAMP signalling and 3 only mutations in other genes encoding GPCR or other 224 
members of the cAMP signalling. The corresponding details are reported in the Table 3. 225 
Finally, a number of altered genes associated at different levels with the Ca2+ signalling and 226 
metabolism (i.e. involving both extra- and intracellular compartment) were observed in 8 cases (22.2% 227 
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of total). They consisted in the α1H subunit of the voltage-dependent T type calcium channel 228 
(CACNA1H), the large subunit of the calpain 1 (CAPN1), the dystrophin (DMD), the NMDA 229 
ionotropic glutamate receptor 2B (GRIN2B), the junctophilin 2 (JPH2), the mannosidase α class 1A 230 
(MAN1A1), the X-linked protocadherin 11 (PCDH11X), the protein interacting with cyclin A1 231 
(PROCA1), the slit homolog 2 (SLIT2), the erythroid α1 spectrin (SPTA1), and the tescalcin (TESC) 232 
(Table 3). 233 
An unsupervised clustering including all the somatic mutations in genes involved in the cAMP 234 
pathway or in the Ca2+ signalling was performed. The results, including the relationship with the total 235 
number of somatic mutations and clinical data is shown in the Figure 2.  236 
Concerning the correlation with the clinical data, the patients with mutations in genes of the 237 
cAMP signalling pathway were mostly females (10/14, 71%), while those with mutations in genes 238 
associated with the Ca2+ signalling were mostly males (5/7, 71%) and those with other kinds of 239 
mutations were equally distributed between the two sexes (50%, P<0.001 by Kruskal-Wallis test for 240 
multiple comparisons) (Figure 2 and Figure 3). A trend to a lower total number of mutations and 241 
younger age was observed in the group of patients without alterations of the cAMP or Ca2+ signalling 242 
in comparison with the other two groups (Figure 2 and Figure 3). No significant differences in terms 243 
of tumor size and basal GH or IGF1 levels have been found. 244 
Functional annotation and pathway analysis: The gene enrichment analysis in the entire series 245 
identified a total of 117 altered genes associated with a gene ontology (GO) term. Several altered 246 
genes resulted to be associated with developmental biological processes (Supplementary table 4). The 247 
canonical pathway analysis recognized no significant overlaps. The gene family analysis showed the 248 
presence of 1 cytokine/growth factor (SLIT2), 7 protein kinases (ADRBK2, CDK10, CHUK, EPHA8, 249 
PRKAA2, SCYL1, TESK1), 4 known oncogenes (GNAS, KDM5A, SH3GL1, STIL) and 2 tumor 250 
suppressor genes (SETD2, TSC2) among the mutated genes.  251 
 252 
Discussion 253 
The present study offers a comprehensive genetic characterization of a large cohort of 67 GH-254 
secreting pituitary adenomas. We aimed to identify novel molecular markers potentially involved in 255 
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tumorigenesis and/or in clinical outcome. To this end, we first performed targeted sequencing of 256 
GNAS, PRKACA and USP8 genes in order to evaluate the presence of mutations in these genes in GH-257 
secreting adenomas, finding only known GNAS gene mutations. By whole-exome sequencing, only a 258 
limited number of genetic alterations have been detected in the 36 evaluated samples. This finding is 259 
consistent with the low mitotic activity of pituitary tumors and with previous small studies on both 260 
non-functioning (n=7)43 and GH-secreting pituitary adenomas (n=12)37. Moreover, no recurrent 261 
somatic mutations have been observed, except the known alterations at the GNAS gene, similarly to a 262 
previous report on a small series of GH-secreting adenomas37. In particular, no somatic mutations have 263 
been also detected at the gene GPR101, probably due to the low reported frequency of this mutations 264 
(11/248 cases)33, and, at both the exome-sequencing and the targeted sequencing, we did not find any 265 
mutations of the PRKACA and USP8 genes. These findings further confirm that both these genetic 266 
alterations are not involved in the pathogenesis of GH-secreting adenomas32, 36. 267 
Interestingly, several non-recurrent alterations affected other genes involved in the cAMP 268 
signalling besides GNAS (see Table 2). These findings further support the view that deregulation of 269 
cAMP pathway is the most important pathogenetic mechanism in GH-secreting adenomas. 270 
Furthermore, a number of genes associated with the Ca2+ signalling (see Table 2) were altered. These 271 
findings are in agreement with another recent study on whole-genome alterations in 12 GH-secreting 272 
adenomas37. This is consistent with the notion that binding of GHRH to its receptor activates not only 273 
the stimulatory subunit α of the G-protein (Gα-S, cAMP-dependent pathways), but also Gα-I, Gβ and 274 
Gγ leading to release of intracellular free Ca2+ , which then further triggers secretion of GH44, 45. 275 
Moreover, ATP, which is co-released with pituitary hormones, induces an increase in free Ca2+ in 276 
pituitary cells46. These data strongly suggest that dysregulation of the calcium signalling might be an 277 
important co-signal in somatothrops and potentially involved in pituitary tumorigenesis. However, its 278 
biological role needs to be better investigated in future functional studies.  279 
It has been suggested that tumors might be very heterogeneous with few mutations in 280 
common. Instead, different genes acting through the same molecular pathways may contribute to 281 
tumor formation47. Therefore, it is possible that at least some of these low-frequency GH-secreting 282 
tumor variants present tumor promoting mutations. Alternatively, they may present other types of 283 
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molecular alterations not detectable by exome-sequencing (i.e. mutations in non-coding intronic 284 
chromosomal regions). 285 
In conclusion, we found no novel recurrently mutated genes in a large series of GH-secreting 286 
pituitary adenomas. However, our and previous genetic findings suggest that beside cAMP pathway, 287 
also different pathways, such as Ca2+ signalling, may play an important role in the pathogenesis of 288 
these tumors.  289 
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Legend to the figures 470 
 471 
Figure 1. Total number of somatic mutations in the 36 GH-secreting pituitary tumors evaluated by 472 
next-generation exome-sequencing (Group 2). The tumors affected by mutations in GNAS are 473 
represented with red bars. The numeration of the GH secreting adenomas is consecutive and do not 474 
correspond to the tumor identification number.  475 
 476 
Figure 2. Overview of the somatic mutations at genes involved in the cAMP signalling (i.e. CCR10, 477 
OR51B4, CHRM3, GNAS, PRKAA2, GRK3, ATP6V0A1) or in the calcium signalling (i.e. CACNA1H, 478 
CAPN1, DMD, GRIN2B, JPH2, MAN1A1, PCDH11X, PROCA1, SLIT2, SPTA1, TESC) in GH-479 
secreting adenomas evaluated by next-generation exome-sequencing (n=36) and relationship with the 480 
total number of somatic mutations, sex, basal GH levels, and tumor extension at the time of diagnosis. 481 
Age: child < 18 years, young ≤50 years (median), old >50 years; tumor size: macro=macroadenoma, 482 
micro=microadenoma; tumor extension: extra=extrasellar, intra=intrasellar; GH: low ≤15 µg/l 483 
(median), high >15 µg/l. 484 
 485 
Figure 3. Relationship between the genetic alterations observed at the exome-sequencing (i.e. 486 
mutations in genes member of the cAMP pathway, of the calcium signalling or in others) and clinical 487 
data (i.e. total number of somatic mutations in upper panel, age in the middle panel; sex in the lower 488 
panel) in 36 evaluated GH-secreting adenomas. 489 
 490 
 491 
Suppl Table 3. List of all genetic alterations observed in 36 GH-secreting pituitary tumors by next-492 
generation exome-sequencing (Group 2), including gene symbols, transcripts and aminoacid 493 
substitutions. 494 
